<DOC>
	<DOCNO>NCT02591199</DOCNO>
	<brief_summary>The purpose study determine combination product ( URG101 ) safe effective versus individual component ( Heparin Sodium Lidocaine Hydrochloride ) treatment Interstitial Cystitis/Bladder Pain Syndrome . The study randomize double-blinded neither subject doctor know drug placebo receive .</brief_summary>
	<brief_title>Evaluation Safety Effectiveness URG101 Subjects With Interstitial Cystitis/Bladder Pain Syndrome</brief_title>
	<detailed_description>This biphasic adaptive design phase 2a , prospective , randomize , double-blind , placebo control , multicenter , single-dose , pharmacokinetic study design determine efficacy safety combination product ( URG101 ) individual component ( Heparin Sodium Lidocaine Hydrochloride ) . The study consist run-in phase 48 subject investigational phase 300 subject . Eligible subject exhibit moderate severe symptom bladder pain associate diagnosis interstitial cystitis/bladder pain syndrome sign informed consent , screen provisionally enrolled intravesical treatment . On day study drug administration subject randomize ( 2:1:2:1 ; URG101 : placebo : lidocaine : heparin ) receive single administration one four intravesical treatment blind fashion , base random assignment : 1 . URG101 ( buffer lidocaine-heparin ) 2 . Placebo 3 . Lidocaine Hydrocholoride buffer alone 4 . Heparin Sodium buffer alone The study 24 hour duration .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Somatoform Disorders</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Subjects diagnose interstitial cystitis/bladder pain syndrome must meet follow criterion participate study : 1 . Have provide write informed consent participate trial 2 . Be male female , ≥ 18 year age 3 . Have moderatetosevere symptom bladder pain bladder origin least 9 month prior study 4 . May may receive cystoscopy association diagnosis interstitial cystitis/bladder pain syndrome prior time screen 5 . Have score ≥ 15 &lt; 30 PUF questionnaire , complete screen 6 . A minimum score 5 require VAS 7 . Have use stable dose hormone therapy ≥ 3 month , female currently take hormone therapy 1 . Pregnant breastfeeding . For female child bear potential male , sexually active , must willing commit acceptable method birth control duration study . 2 . Have know hypersensitivity heparin lidocaine 3 . Have use local anesthetic route within 24 hour prior study drug administration , use lidocaine patch within 14 day prior study drug administration 4 . Have use tricyclic antidepressant unless take medication ≥ 3 month Neurontin® within 21 day prior receive study drug 5 . Have use pain medication within 6 hour prior study drug administration 6 . Have use narcotic medical marijuana ≤ 3 week prior study entry ( generic name : codeine , fentanyl , hydrocodone , hydromorphone , levorphanol , medical marijuana , methadone , morphine , oxycodone , propoxyphene , tramadol ) 7 . Have use prohibit drug determine selfreport , positive urine drug screen , opinion investigator influence drug affect mentation preclude ability follow study protocol bias study result 8 . Have know clinically significant abnormal laboratory test value define investigator 9 . Have neurogenic bladder disorder , opinion investigator , may cause neurogenic bladder ( include Parkinson 's disease , multiple sclerosis , epilepsy , myasthenia gravis , movement disorder , spinal cord damage ) 10 . Have pain pain disorder , opinion investigator , would make difficult discriminate pelvic pain bladder origin pain 11 . Have severe depression , bipolar disorder , schizophrenia , anxiety , attention deficit disorder , obsessive compulsive disorder , major central nervous system disorder 12 . Have history arrhythmia , conduction disturbance , cardiac disease , coexist medical condition , opinion investigator , may significant interfere study procedure interpretation study result 13 . Had bladder instillation therapy within 7 day prior study entry prior bladder instillation heparin lidocaine respond 14 . Had dilatation ( hydrodistention ) bladder within 3 month study entry 15 . Evidence suspect presence cancer detect cystoscopy prior time initial screening . 16 . Has receive investigational drug device within 30 day prior screen 17 . Is currently enrol another investigational drug device study 18 . Is unwilling unable abide requirement study 19 . Have actively bleed lesion area bladder detect dipstick urinalysis investigator assessment , immediately prior randomization 20 . Have follow : bacterial , chemical ( include ketamine cyclophosphamide ) radiation cystitis ; gynecological , urological rectal cancer ; current chemotherapy ; tuberculous cystitis ; urinary schistosomiasis ; bladder uretal calculus ; vaginitis genital herpes ; urethral diverticulum bladder fistula .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>